Fate Therapeutics (FATE) Competitors $1.46 -0.09 (-5.52%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. RZLT, NRIX, DAWN, AKBA, OLMA, TYRA, TERN, TBPH, ARVN, and ERASShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Rezolute (RZLT), Nurix Therapeutics (NRIX), Day One Biopharmaceuticals (DAWN), Akebia Therapeutics (AKBA), Olema Pharmaceuticals (OLMA), Tyra Biosciences (TYRA), Terns Pharmaceuticals (TERN), Theravance Biopharma (TBPH), Arvinas (ARVN), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Its Competitors Rezolute Nurix Therapeutics Day One Biopharmaceuticals Akebia Therapeutics Olema Pharmaceuticals Tyra Biosciences Terns Pharmaceuticals Theravance Biopharma Arvinas Erasca Fate Therapeutics (NASDAQ:FATE) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Which has higher valuation and earnings, FATE or RZLT? Rezolute has lower revenue, but higher earnings than Fate Therapeutics. Rezolute is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M12.31-$186.26M-$1.45-1.00RezoluteN/AN/A-$74.41M-$0.97-8.85 Do institutionals & insiders believe in FATE or RZLT? 97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 5.5% of Fate Therapeutics shares are owned by insiders. Comparatively, 14.8% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer FATE or RZLT? Fate Therapeutics currently has a consensus price target of $3.30, indicating a potential upside of 126.80%. Rezolute has a consensus price target of $14.50, indicating a potential upside of 68.86%. Given Fate Therapeutics' higher probable upside, research analysts plainly believe Fate Therapeutics is more favorable than Rezolute.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 1 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Rezolute 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Does the media prefer FATE or RZLT? In the previous week, Fate Therapeutics had 4 more articles in the media than Rezolute. MarketBeat recorded 5 mentions for Fate Therapeutics and 1 mentions for Rezolute. Rezolute's average media sentiment score of 0.50 beat Fate Therapeutics' score of 0.34 indicating that Rezolute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is FATE or RZLT more profitable? Rezolute has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,025.05%. Fate Therapeutics' return on equity of -50.95% beat Rezolute's return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-2,025.05% -50.95% -36.76% Rezolute N/A -65.03%-58.86% Which has more volatility & risk, FATE or RZLT? Fate Therapeutics has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Rezolute has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. SummaryFate Therapeutics and Rezolute tied by winning 8 of the 16 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$167.81M$3.41B$6.08B$10.51BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-1.0022.5084.1027.01Price / Sales12.31481.27607.14130.56Price / CashN/A46.9737.8662.13Price / Book0.5210.4112.236.56Net Income-$186.26M-$52.47M$3.32B$276.88M7 Day Performance-11.01%1.72%0.46%0.68%1 Month Performance53.16%13.86%7.73%3.86%1 Year Performance-54.81%12.07%70.73%34.96% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics4.1822 of 5 stars$1.46-5.5%$3.30+126.8%-52.0%$167.81M$13.63M-1.00550RZLTRezolute2.4649 of 5 stars$8.07-2.4%$14.50+79.7%+79.2%$751.15MN/A-8.3240NRIXNurix Therapeutics1.8875 of 5 stars$9.72-0.4%$27.93+187.3%-61.1%$750.38M$54.55M-3.27300Trending NewsAnalyst ForecastAnalyst RevisionDAWNDay One Biopharmaceuticals3.1376 of 5 stars$7.19-0.7%$25.29+251.7%-50.2%$741.61M$131.16M-7.5760Gap DownAKBAAkebia Therapeutics3.5941 of 5 stars$2.78+1.1%$6.75+142.8%+119.5%$729.15M$160.18M-16.35430OLMAOlema Pharmaceuticals3.0003 of 5 stars$10.75+1.7%$23.33+117.1%-22.0%$725.47MN/A-5.4370TYRATyra Biosciences2.5207 of 5 stars$14.36+6.2%$31.86+121.8%-42.7%$720.58MN/A0.0020TERNTerns Pharmaceuticals4.0812 of 5 stars$8.20+0.6%$15.49+88.9%+12.5%$713.22MN/A-7.8840News CoverageAnalyst ForecastTBPHTheravance Biopharma3.2392 of 5 stars$13.92-0.5%$23.00+65.2%+61.4%$704.55M$64.38M58.00110News CoverageARVNArvinas3.5345 of 5 stars$9.80+3.6%$16.29+66.2%-65.2%$694.53M$263.40M-9.70420Analyst DowngradeGap DownHigh Trading VolumeERASErasca2.8724 of 5 stars$2.40-0.4%$3.71+54.8%-11.2%$683.65MN/A-5.33120Analyst Forecast Related Companies and Tools Related Companies Rezolute Alternatives Nurix Therapeutics Alternatives Day One Biopharmaceuticals Alternatives Akebia Therapeutics Alternatives Olema Pharmaceuticals Alternatives Tyra Biosciences Alternatives Terns Pharmaceuticals Alternatives Theravance Biopharma Alternatives Arvinas Alternatives Erasca Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
